We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

NT-proBNP in Acute Dyspnea: Effects on Treatment, Hospitalisation and Costs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00410293
Recruitment Status : Completed
First Posted : December 12, 2006
Last Update Posted : December 12, 2006
Information provided by:
Erasmus Medical Center

Brief Summary:

Diagnostic uncertainty in patients with complaints of shortness of breath presenting to the Emergency Department of a hospital may delay treatment and proper care. In patients with shortness of breath due to heart failure increased plasma levels of NT-pro-B-type natriuretic peptide (NT-proBNP) can be demonstrated. The use of NT-proBNP as a biomarker for heart failure in patients presenting to the emergency department with dyspnea might improve care and reduce length of hospital stay.

To investigate the effect of NT-proBNP testing on patient care and time to discharge the NT-proBNP test will be randomized. In patients in the study group, the NT-proBNP plasma level is determined at admission and the physician in charge will immediately receive the result of the test. In patients in the control group blood will be sampled but the physician will recieve no information on the NT-proBNP plasma level.

In our study we will investigate the effect of introduction of NT-proBNP as biomarker for heart failure on treatment, time to discharge and costs.

Condition or disease Intervention/treatment
Heart Failure Dyspnea Procedure: NT-proBNP testing

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Diagnostic
Official Title: NT-proBNP Testing in Patients Presenting to the Emergency Department With Acute Dyspnea: Evaluation of Effects on Treatment, Hospitalisation Rate and Costs
Study Start Date : December 2004
Estimated Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Time to discharge
  2. Cost of treatment

Secondary Outcome Measures :
  1. Duration of stay at the ED
  2. Proportion of patients admitted to the hospital
  3. Proportion of patients admitted to an intensive or coronary care unit
  4. Specialist consultations
  5. Medical treatment
  6. Diagnostic investigations

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or older
  • Acute dyspnea as their most prominent complaint

Exclusion Criteria:

  • Acute dyspnea due to a trauma
  • Acute dyspnea due to cardiogenic shock
  • Renal failure requiring dialysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00410293

Erasmus MC
Rotterdam, Netherlands, 3015 CE
Sponsors and Collaborators
Erasmus Medical Center
Principal Investigator: Anton H. van den Meiracker, MD, PhD Erasmus MC, Rotterdam, the Netherlands

ClinicalTrials.gov Identifier: NCT00410293     History of Changes
Other Study ID Numbers: MEC-2004-201
First Posted: December 12, 2006    Key Record Dates
Last Update Posted: December 12, 2006
Last Verified: December 2006

Keywords provided by Erasmus Medical Center:
Heart failure
Natriuretic peptide
NT-pro B-type natriuretic peptide
Length of stay

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms